Sichuan Kelun-biotech Biopharmaceutical Co., Ltd.

Dell Products Inc.

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd.

Qilu Pharmaceutical Co., Ltd.

Klus Pharma Inc.

Chinese Academy of Sciences

Sichuan Kelan Pharmaceutical Research Institute Co., Ltd.

Sichuan Kelun-biotech Biopharmaceuticals Co., Ltd.

Sichuan Keiun-biotech Biopharmaceutical Co., Ltd.

Jingyi Wang

Lichun Wang

Qiang Tian

Jiaqiang Cai

Hongmei Song

Tongtong Xue

Hong Zeng

Liang Xiao

Shuai Song

Mingliang Zhao

Dengnian Liu

Yang Zhang

Dong Zhao

Shuangshuang Liang

Fengying Shan

Yongyong Wu

Zhengxing Su

Likai Yang

Hanwen Deng

Donghai Su

Dong Long

Jing Wang

Yao Liu

Guoqing Zhong

Wei Zhong

Tianming Wang

Haitao Huang

Chengxi Yang

Zujian Tang

Rongrong Long

Yu Xia

Baiyong Li

Zhongmin Maxwell Wang

Long Zhang

Chaojun Zhao

Jinming Liu

Wei Liu

Chuanwen Fan

Cheng Wang

Minghui Zhang

Zejin You

Zhiwen Deng

Jun Zhu

Yinong Xie

Yan Feng

Qijun Ye

Wei Qi

Ao Wang

Baolei Zhang

Chaolei Wang

Yufeng Liang

Sujun Deng

Xiaofan Duan

Haijun Tian

Qingmin Yang

Allen Zhao

Yan Qing

Yujun Wang

Kexing Wang

Xiaoxi Yuan

Hu Long

Shousheng Yan

Nan Yu

Hua Deng

Jiawang Zhu

Liping Liu

Xin Zhou

Zhiquan Song

Yuting Tan

Jianhua Ge

Jing Zhou

Qiang Li

Gang Chen

Zhenwei Miao

Si Ruo Chen

Hong Zhang

Tong Zhu

Weilan Pu

Wesley Wei Sun

Ying Wang

Yuncheng Zheng

Xiao Le Shang

Qiang Zhang

Jianrong Zhu

Zongru Guo

Yong Gan

Zhantao Zhang

Ping Zhang

Ping Liu

Chunliu Zhu

Hong Li

Ruibin Hu

Yitao Zhang

Yongjia Hao

Jiangfeng Zhou

Fulu Zhao

Jianfeng Han

Hong Ye

Gang Liu

Methods, system, and non-transitory processor-readable storage medium for a test selection system are provided herein. An example method includes selecting, by a test selection system, a regression test case from a plurality of regression test cases in a software testing lifecycle system. The test selection system determines a product release weight associated with the regression test case, where the product release weight incorporates new features associated with a product release. The test selection system obtains a regression test case value for the regression test case by applying the product release weight. The test selection system selects the regression test case for use in regression testing for the product release, based on the regression test case value and executes the regression test case on a system.

Intelligent way to select regression test cases in system test

An apparatus comprises a processing device configured to determine syncing progress metrics for replication sessions established between a source and a destination storage system, each of the replication sessions being associated with a recovery point objective and having an assigned bandwidth quota. The processing device is also configured to identify whether a first replication session is not expected to meet its associated first recovery point objective based at least in part on its determined first syncing progress metric and whether at least a second replication session is expected to meet its associated second recovery point objective based at least in part on its determined second syncing progress metric. The processing device is further configured, responsive to identifying the first and second replication sessions, to update a first assigned bandwidth quota for the first replication session and a second assigned bandwidth quota for the second replication session.

Managing bandwidth quotas for replication sessions established between source and destination storage systems

Provided herein is an anti-CLDN18.2 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding the antibody and fragment, and method for preparing the antibody and fragment. The anti-CLDN18.2 antibody or the antigen-binding fragment thereof has high specificity and affinity to CLDN18.2, and can effectively bind to CLDN18.2 and mediate the killing of CLDN18.2 expressing cells. Also provided herein is a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use thereof in the preparation of drugs for the prevention and/or treatment of tumors.

Antibody and use thereof

A compound represented by formula (I) or a pharmaceutically acceptable salt, a stereoisomer, a tautomer, a polymorph, a solvate, an N-oxide, an isotope labeled compound, a metabolite or a prodrug thereof, a pharmaceutical composition and a pill container comprising same, a preparation method therefor, and the use thereof in the preparation of drugs for preventing or treating STING-mediated related diseases.

Benzothiophene compound, preparation method therefor and use thereof

The present invention relates to the field of therapeutic monoclonal antibodies, and specifically provides an anti-FXI/FXIa antibody or an antigen-binding fragment thereof, nucleic acid molecules encoding same, and methods for preparing same. The anti-FXI/FXIa antibody or antigen-binding fragment thereof described in the present invention has specificity and high affinity to FXI/FXIa, and can effectively inhibit the activity of FXI/FXIa. Therefore, the present invention further provides a pharmaceutical composition comprising the antibody or antigen-binding fragment thereof, and a use thereof in the preparation of a drug which is used for the prevention and/or treatment of diseases or disorders related to coagulation or thromboembolism.

Anti-FXI/FXIa antibody and use thereof

Disclosed in the present invention is the use of an anti-HER2 antibody-drug conjugate in cancer treatment. Further provided in the present invention is the use of a pharmaceutically acceptable salt, stereoisomer, or metabolite thereof, or a solvate of each of the foregoing in the manufacture of a medicament for the prophylaxis and/or treatment of a cancer insensitive or irresponsive to a treatment with a HER2-targeting agent.

Use of anti-HER2 antibody-drug conjugate in cancer treatment

Automatic file system capacity management techniques are provided using file system utilization prediction. One method comprises obtaining input data representing a utilization of a storage capacity of a file system of a given storage system; predicting a future utilization of the storage capacity of the file system based on a portion of the obtained input data; and automatically adjusting the storage capacity of the file system based at least in part on a result of a comparison of the predicted utilization of the storage capacity to a current utilization of the storage capacity. The comparison of the predicted utilization to a current utilization of the storage capacity may comprise comparing the current utilization of the storage capacity to the predicted utilization of the storage capacity for at least first and second time periods following a current time period to determine a trend of the utilization of the storage capacity.

Automatic file system capacity management using file system utilization prediction

Storage processes are described. For instance, dumping of cache data in a memory table at a source directory table partition in a source container group is stopped in response to receiving a close signal. A notification for creating a target directory table partition is sent to a target container group, the notification including a checkpoint at the source directory table partition. The cache data in the memory table is sent to the target container group, and the source container group is closed in response to a determination that an ownership of the target directory table partition is updated to the target container group. A rescheduling and/or upgrading solution is thus proposed for a source container group, so that the source container group is still in a service state during the rescheduling and/or upgrading solution, which improves the performance of storage services and reduces the data unavailable time.

Method, device, and computer program product for storage

Dynamic snapshot scheduling techniques are provided using storage system metrics. One method comprises obtaining a schedule for generating snapshots of a portion of a storage system; automatically adjusting snapshot generation parameters in the schedule based on: (i) a current storage pool usage metric, (ii) an input/output metric of at least one storage resource in the portion of the storage system, (iii) a measure of snapshots in a destroying state, and/or (iv) a measure of a number of created snapshots; and initiating a generation of a snapshot of the storage system portion in accordance with the adjusted schedule. A snapshot generation frequency may be increased in response to an increase of: the current storage pool usage metric, the number of snapshots in the destroying state, and/or the number of created snapshots. A snapshot generation frequency may be decreased in response to an increase of the I/O metric of the at least one storage resource.

Dynamic snapshot scheduling using storage system metrics

Provided herein are bioactive molecule conjugates, preparation methods and use thereof, particularly bioactive molecule conjugates (such as antibody-drug conjugates and small molecule drug conjugates) obtained by improved coupling of a drug and a targeting moiety, as well as their preparation method and use for the treatment of a disease associated with an abnormal cell activity.

Bioactive molecule conjugate, preparation method and use thereof

Disclosed herein is an albumin pharmaceutical composition, comprising albumin and at least one amino acid having a relative molecular mass of 145-175. Clinically, the albumin pharmaceutical composition can effectively reduce undesirable responses, such as rash, urticaria, anaphylaxis and possible immune responses in the human body caused by albumin polymers and dimers, thereby further ensuring the safety in clinical medication.

Albumin pharmaceutical composition and preparation method therefor

Provided is a preparation method of an antibody-drug conjugate represented by Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof, or a solvate of the foregoing,

Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof

The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.

Isoxazole derivative, preparation method therefor, and use thereof

The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune response, or are used for preventing and/or treating tumors, infections or autoimmune diseases.

Anti-LAG-3 antibody and use thereof

Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.

Tetrahydroisoquinoline derivatives, preparation process and use thereof

Growing community of inventors

Chengdu, China

Jingyi Wang